IMM2520 is a CD47×PD-L1 bispecific molecule for the treatment of solid tumors. By targeting CD47 and PD-L1 on tumor cells and with its unique design, IMM2520 can simultaneously activate macrophages and T cells to achieve strong synergistic effects and trigger lasting immune responses against tumors.

IMM2520 showed in vivo efficacy and safety in several animal models. We have obtained IND approvals for IMM2520 from the NMPA in November 2022 and from the FDA in December 2022, and dosed the first patient for the Phase I clinical trial in China in March 2023. We will primarily focus on the solid tumors generally resistant or not sensitive to the currently available immunotherapies, such as colorectal cancer (CRC), gastric cancer (GC), lung cancer and head and neck squamous cell carcinomas (HNSCC), among others. With further clinical validation from the Phase I trial in China, the Company will carefully decide whether to proceed with a clinical trial or explore potential collaboration opportunities in the U.S.